おすすめの製品
由来生物
human
品質水準
包装
vial of ≥1 x 10^6 vial (viable cells per vial)
メーカー／製品名
Millipore
テクニック
cell culture | mammalian: suitable
輸送温度
liquid nitrogen
保管温度
−196°C
アプリケーション
- Each vial contains > 1X106 viable cells.
- Cells are tested negative for infectious diseases by Essential CLEAR Panel by Charles River Animal Diagnostic Services.
- Cells are verified to be of human origin and negative for interspecies contamination from human, rat, Chinese hamster, Golden Syrian hamster, and nonhuman primate (NHP) as assessed by a Contamination Clear panel by Charles River Animal Diagnostic Services
- Cells are negative for mycoplasma contamination.
特徴および利点
HCI-EC-23 is an estrogen and progesterone responsive cell line that can be used to study the hormonal aspects of endometrial cancer.
ターゲットの説明
Endometrial cancer, a sub-type of uterine cancer, affects the inner lining of the uterus also known as the endometrium. Endometrial cancer is categorized into two primary subtypes, Type I and Type II. Type I tumors are typically characterized by their high levels of estrogen receptor alpha (ERα). These tumors are also thought to be driven by excessive estrogen signaling. Type II endometrial tumors are considered to be hormone-independent and may have a mixed histological background.
A variety of cell lines have been created from Type I tumors such as Ishikawa cells. However, many of these cell lines have lost ERα expression and estrogen response. The limited availability of ERα expressing endometrial cell lines limits the variety of genetic backgrounds for understanding endometrial cancer. Patient derived xenografts (PDX) have increased the capability to produce hormone-responsive models but lack some of the benefits of a cell line model.
The HCI-EC-23 human endometrial cancer cell line was derived by generating a PDX cell line in a mouse model. Cells from an endometrial carcinoma sample were injected into immunodeficient mice and grown in the mouse model before being harvested. PDX samples were dissociated, grown on collagen coated plates and selected for predominantly human (99%) cells which became the HCI-EC-23 cell line. These cells retain ER expression and estrogen-responsiveness in vitro and in vivo. The cell line contains important mutations relevant to endometrial carcinomas including mutations at PTEN, PIK3CA, ARID1A, CTCF, and ATM, but remains wild-type for PIK3R1, CTNNB1, KRAS and TP53. Progesterone receptor genes and estrogen receptor genes also remain wild-type.
Estrogen responsiveness was tested in the HCI-EC-23 cell line by transfecting cells with a luciferase reporter under control of tandem estrogen response elements and treating cells with E2. HCI-EC-23 cells also showed estrogen responsiveness to 4-hydroxy-tamoxifen (4OHT) treatment which is consistent with observations of endometrial response.
Source: Primary tumor was obtained from a 66-year old woman diagnosed with Grade 2 Stage 1A endometrioid endometrial carcinoma which was later cloned into a mouse PDX model. A predominantly human (99%) cell outgrowth was used to derive the HCI-EC-23 human endometrial cancer cell line.
References
1. Rush, C.M., Blanchard, Z., Polaski, J.T. et al. Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line. Sci Rep 12, 19731 (2022).
A variety of cell lines have been created from Type I tumors such as Ishikawa cells. However, many of these cell lines have lost ERα expression and estrogen response. The limited availability of ERα expressing endometrial cell lines limits the variety of genetic backgrounds for understanding endometrial cancer. Patient derived xenografts (PDX) have increased the capability to produce hormone-responsive models but lack some of the benefits of a cell line model.
The HCI-EC-23 human endometrial cancer cell line was derived by generating a PDX cell line in a mouse model. Cells from an endometrial carcinoma sample were injected into immunodeficient mice and grown in the mouse model before being harvested. PDX samples were dissociated, grown on collagen coated plates and selected for predominantly human (99%) cells which became the HCI-EC-23 cell line. These cells retain ER expression and estrogen-responsiveness in vitro and in vivo. The cell line contains important mutations relevant to endometrial carcinomas including mutations at PTEN, PIK3CA, ARID1A, CTCF, and ATM, but remains wild-type for PIK3R1, CTNNB1, KRAS and TP53. Progesterone receptor genes and estrogen receptor genes also remain wild-type.
Estrogen responsiveness was tested in the HCI-EC-23 cell line by transfecting cells with a luciferase reporter under control of tandem estrogen response elements and treating cells with E2. HCI-EC-23 cells also showed estrogen responsiveness to 4-hydroxy-tamoxifen (4OHT) treatment which is consistent with observations of endometrial response.
Source: Primary tumor was obtained from a 66-year old woman diagnosed with Grade 2 Stage 1A endometrioid endometrial carcinoma which was later cloned into a mouse PDX model. A predominantly human (99%) cell outgrowth was used to derive the HCI-EC-23 human endometrial cancer cell line.
References
1. Rush, C.M., Blanchard, Z., Polaski, J.T. et al. Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line. Sci Rep 12, 19731 (2022).
保管および安定性
HCI-EC-23 cells should be stored in liquid nitrogen. The cells can be cultured for at least 10 passages without significantly affecting cell marker expression and function.
その他情報
This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
保管分類コード
10 - Combustible liquids
WGK
WGK 2
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
SCC641:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）